Tom Estok is the founder of Dracen Pharmaceuticals. Dracen Pharmaceuticals has raised $40M in total funding. Latest round: Series A.
Tom Estok serves as the Chief Executive Officer of Dracen Pharmaceuticals, a privately-funded biotech company that develops proprietary glutamine antagonists for the treatment of cancers and autoimmune/inflammatory diseases. The company recently closed a $40 million Series A financing round led by Deerfield Management.
Full founder directory · Investor directory · Company funding database · Fundraising library